Vineti, a leading digital platform of record for personalized therapeutics, announced the closing of a $33 million extension to its Series C financing round. The new financing will support further expansion of the company’s Personalized Therapy Management (PTM)® platform for personalized and high-value advanced therapies.
The Series C extension is led by Cardinal Health, with participation from Marc Benioff and existing Vineti investors including McKesson Ventures, Novartis Pharma AG, LifeForce Capital, Threshold Ventures (formerly DFJ), Section 32, Casdin Capital, and other undisclosed entities. Eli Casdin, chief investment officer and founder of Casdin Capital, will join Vineti’s Board of Directors.
Vineti offers an independent, purpose-built enterprise solution that enables the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations.
Vineti’s diverse set of investors mirrors the company’s hybrid team that offers a unique blend of biopharmaceutical and technological expertise that gives the company and its platform distinct advantages in solving the operational challenges faced by advanced therapies.
This extension to the Series C round brings Vineti’s publicly announced financing to more than $115 million.
“2020 has driven one key point home—the continued success of advanced therapies relies on standardized, dependable infrastructure,” said Vineti CEO and Co-founder Amy DuRoss. “Vineti was built for purpose to serve personalized medicine. We’re now very humbled and honored by the direct support of key industry leaders, including a biopharmaceutical commercialization standard-setter and an enterprise cloud computing pioneer. We are also very excited to be adding such a leading and insightful investor in Eli Casdin to our corporate board, as we continue to expand Vineti’s brain trust overall on behalf of our growing industry.”
Read the original press release here.